Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan Phase 3b validation of French, Italian and Spanish PAH-SYMPACT
2013-003462-14Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Psychometric validation of French PAH-SYMPACT, Psychometric validation of Italian PAH-SYMPACT and 1 more. Started Nov 2013; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2013-003462-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003462-14.